Symposium: AHA Council on Basic Cardiovascular Sciences

描述（由申请人提供）： 这项多年会议资助申请（R13）寻求NHLBI支持，以建立由美国心脏协会基础心血管科学理事会（世界领先的心血管科学家组织）赞助的年度研讨会。在阿西洛马、雪鸟和西雅图举行的更零星的会议的演变，这次年度会议将进一步的科学使命，以了解从分子、细胞和组织到器官、器官系统和生物体的无缝连续的正常和异常心血管生物学。在当前所谓的“后基因组”时代，随着人类基因组测序的完成，我们的许多观众都非常关注将基因与心血管系统功能联系起来。通过意图，我们已经取代了前几年使用的“心力衰竭”和“梗死”的交替主题，对功能基因组学进行了更加综合和广泛的科学关注。2004年，这次会议的统一科学主题将是心血管系统对压力的全基因组反应，这是一个当前特别有吸引力的主题。国家在心脏病方面的战略目标不能仅仅通过现成的药物、设备和生活方式的改变来实现。主要的治疗挑战包括通过抑制心肌细胞死亡、通过促进细胞存活信号以及通过供应或激活干细胞作为实现心肌修复的手段来挽救急性缺血性心脏病和充血性心力衰竭中的心肌。成体干细胞在这些方面的潜在效用甚至超过了几年前最乐观的预测，这反映在世界范围内已经进行的临床试验数量上。第一届年度研讨会将于2004年7月14日至18日在华盛顿的史蒂文森举行，由Michael Schneider博士、Ivor Benjamin博士、Issei Komuro博士和Stefanie Dimmeler博士组织。施耐德博士担任这个具有里程碑意义的会议赠款提案的PI。

DESCRIPTION (provided by applicant): This multiple-year conference grant application (R13) seeks NHLBI support towards the establishment of an annual symposium sponsored by the American Heart Association's Council on Basic Cardiovascular Sciences, the world's leading organization of cardiovascular scientists. An evolution of more sporadic meetings held in Asilomar, Snowbird, and Seattle, this annual conference would further the scientific mission to understand normal and abnormal cardiovascular biology in seamless continuity from molecules, cells, and tissues to organs, organ systems, and organisms. In the current so-called "post-genomic" era, with the human genome sequencing complete, an intensely shared focus for much of our audience is linking genes to function in the cardiovascular system. By intent, we have superceded the alternating themes of "heart failure" and "infarction" used in prior years, with a much more integrated and broadly based scientific focus on functional genomics. For 2004, the unifying scientific theme of this conference will be the genome-wide response to stress in the cardiovascular system, a topic of especially current appeal. National strategic goals in heart disease cannot be met with off-the-shelf drugs, devices, and life-style modifications alone. Major therapeutic challenges include salvaging myocardium in acute ischemic heart disease and in congestive heart failure by inhibiting cardiac muscle cell death, by promoting cell survival signals, and by supplying or activating stem cells as a means to achieve myocardial repair. The potential utility of adult stem cells for these purpose exceeds even the most optimistic projections of a few years ago, and is reflected by the number of clinical trials already underway worldwide. The 1st Annual Symposium will be held July 14-18, 2004, in Stevenson, Washington, and was organized by Drs. Michael Schneider, Ivor Benjamin, Issei Komuro, and Stefanie Dimmeler. Dr. Schneider serves as the PI for this landmark conference grant proposal.